首页 | 本学科首页   官方微博 | 高级检索  
检索        

曲妥珠单抗和帕妥珠单抗联合化疗对HER2阳性乳腺癌新辅助治疗的真实世界研究
引用本文:马祥敏,张香梅,周新平,任晓菲,张玮芳,刘运江.曲妥珠单抗和帕妥珠单抗联合化疗对HER2阳性乳腺癌新辅助治疗的真实世界研究[J].肿瘤防治研究,2022,49(1):46-52.
作者姓名:马祥敏  张香梅  周新平  任晓菲  张玮芳  刘运江
作者单位:1. 056001 邯郸,邯郸市中心医院乳腺外科;2. 050011 石家庄,河北医科大学第四医院科研中心;3. 050011 石家庄,河北医科大学第四医院乳腺中心
基金项目:河北省重点研发计划项目(192777125D);河北省自然科学基金(H2020206210);河北省卫生健康委医学科学研究课题计划项目(20210946)。
摘    要:目的 分析曲妥珠单抗(H)和帕妥珠单抗(P)联合化疗对HER2阳性乳腺癌新辅助治疗的疗效和安全性.方法 回顾性分析行HP联合化疗新辅助治疗并完成手术的HER2阳性乳腺癌患者的临床资料,主要研究终点为总体病理完全缓解(tpCR)(ypT0/isypN0),次要研究终点为乳腺病理完全缓解(bpCR)(ypT0/is)和腋窝...

关 键 词:乳腺癌  HER2  新辅助治疗  曲妥珠单抗  帕妥珠单抗  病理完全缓解

Real-world Research of Trastuzumab and Pertuzumab Combined with Chemotherapy in Neoadjuvant Treatment of HER2-positive Breast Cancer
MA Xiangmin,ZHANG Xiangmei,ZHOU Xinping,REN Xiaofei,ZHANG Weifang,LIU Yunjiang.Real-world Research of Trastuzumab and Pertuzumab Combined with Chemotherapy in Neoadjuvant Treatment of HER2-positive Breast Cancer[J].Cancer Research on Prevention and Treatment,2022,49(1):46-52.
Authors:MA Xiangmin  ZHANG Xiangmei  ZHOU Xinping  REN Xiaofei  ZHANG Weifang  LIU Yunjiang
Institution:1. Department of Breast Surgery, Handan Central Hospital, Handan 056001, China; 2. Research Center, Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China; 3. Breast Center, Fourth Hospital of Hebei Medical University Shijiazhuang 050011, China
Abstract:Objective To analyze the efficacy and safety of trastuzumab (H) and pertuzumab (P) combined with different chemotherapy regiments in neoadjuvant therapy for HER2-positive breast cancer. Methods We retrospectively analyzed the clinical data of the patients with HER2-positive breast cancer who received HP combined with chemotherapy as neoadjuvant therapy and completed surgery. The primary endpoint was total pathologic complete response (tpCR) (ypT0/isypN0), the secondary endpoints were breast pathologic complete response(bpCR) (ypT0/is) and axillary pathologic complete response (apCR) (ypN0), and the factors influencing pCR were analyzed. Results A total of 63 patients were included, of whom 23 were treated with TCbHP, 27 were treated with THP regimen, and 13 were treated with AC-THP. The overall tpCR rate was 65.1%, of which TCbHP was 73.9%, THP was 55.6%, and AC-THP was 69.2%. The tpCR rate of HR-negative patients was 79.2%, higher than that of HR-positive 56.4%. The overall bpCR rate was 69.8%, and apCR rate was 81.0%. Univariate analysis showed that HER2 status was a related factor affecting tpCR (P=0.023). The total effective rate by MRI was 87.3%. The level 3 and 4 toxicity of the TCbHP regimen was slightly higher than those of the THP and the AC-THP regimens. Conclusion HP combined with chemotherapy have achieved relatively high pCR. HER2 status is a related factor that affects tpCR. The adverse reactions are controllable.
Keywords:Breast cancer  HER2  Neoadjuvant therapy  Trastuzumab  Pertuzumab  Pathological complete response
本文献已被 维普 等数据库收录!
点击此处可从《肿瘤防治研究》浏览原始摘要信息
点击此处可从《肿瘤防治研究》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号